Oxidized glycerophosphatidylcholines in diabetes through non-targeted metabolomics: Their annotation and biological meaning.


Journal

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
ISSN: 1873-376X
Titre abrégé: J Chromatogr B Analyt Technol Biomed Life Sci
Pays: Netherlands
ID NLM: 101139554

Informations de publication

Date de publication:
01 Jul 2019
Historique:
received: 25 03 2019
revised: 26 04 2019
accepted: 28 04 2019
pubmed: 10 5 2019
medline: 14 6 2019
entrez: 10 5 2019
Statut: ppublish

Résumé

Lipid oxidation is one of the most important processes occurring in living cells and has been investigated through stable end-products. Currently, new insights into many physiological and pathophysiological processes provide a measurement of the first products of oxidation, e.g., oxidized glycerophosphatidylcholines (oxGPCs). Here, we evaluate the capacity of untargeted global metabolomics to measure oxGPCs in serum samples. This evaluation covered analytical reproducibility and data quality as well as the ability to capture metabolic alterations in diverse conditions. The analytical evaluation was performed based on the quality control samples, while the comparative analysis was based on the model of the development of type 2 diabetes mellitus (T2DM). The novelty of this approach arises not only from the measurement of oxGPCs instead of lipid peroxide-derived aldehydes but also from the stratification of the patients according to body mass index (BMI). Such a scenario was dictated by the fact that, despite the well-known relationship between obesity and T2DM development, there are lean individuals suffering from T2DM as well as obese people with normal glucose homeostasis. Our results provided evidence to support the ability of nontargeted metabolomics to measure oxGPCs. Comparative analysis of measured oxGPCs revealed differences in the level of oxGPCs either between different stages of disease development (insulin resistance, prediabetes) or BMI groups (normal weight, overweight, obese). The obtained results provided new insights into the metabolic processes leading to the development of T2DM and opened new paths in the investigation of the impact of body mass in T2DM progress.

Identifiants

pubmed: 31071580
pii: S1570-0232(19)30490-8
doi: 10.1016/j.jchromb.2019.04.053
pii:
doi:

Substances chimiques

Glycerylphosphorylcholine 60M22SGW66

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

62-70

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Joanna Godzien (J)

Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland; CEMBIO, Centre for Metabolomics and Bioanalysis, San Pablo CEU University, Madrid, Spain.

Bartlomiej Kalaska (B)

CEMBIO, Centre for Metabolomics and Bioanalysis, San Pablo CEU University, Madrid, Spain; Department of Pharmacodynamics, Medical University of Bialystok, Bialystok, Poland.

Edyta Adamska-Patruno (E)

Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.

Jitka Siroka (J)

CEMBIO, Centre for Metabolomics and Bioanalysis, San Pablo CEU University, Madrid, Spain; Laboratory of Growth Regulators, The Czech Academy of Sciences, Institute of Experimental Botany & Palacký University, Faculty of Science, Olomouc, Czech Republic; Laboratory of Metabolomics, Institute of Molecular and Translational Medicine, Palacký University in Olomouc, Olomouc, Czech Republic.

Michal Ciborowski (M)

Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.

Adam Kretowski (A)

Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.

Coral Barbas (C)

CEMBIO, Centre for Metabolomics and Bioanalysis, San Pablo CEU University, Madrid, Spain. Electronic address: cbarbas@ceu.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH